The estimated Net Worth of Eric A Md Rose is at least $8.91 Million dollars as of 15 June 2021. Eric Rose owns over 15,000 units of SIGA Technologies Inc stock worth over $8,025,133 and over the last 19 years he sold SIGA stock worth over $566,475. In addition, he makes $319,500 as Chairman of the Board at SIGA Technologies Inc.
Eric has made over 18 trades of the SIGA Technologies Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of SIGA stock worth $112,650 on 15 June 2021.
The largest trade he's ever made was exercising 400,000 units of SIGA Technologies Inc stock on 20 August 2018 worth over $996,000. On average, Eric trades about 28,549 units every 97 days since 2005. As of 15 June 2021 he still owns at least 1,068,593 units of SIGA Technologies Inc stock.
You can see the complete history of Eric Rose stock trades at the bottom of the page.
Dr. Eric A. Rose M.D. serves as Chairman of the Board of the Company. Dr. Rose’s was appointed Chairman of the Board of Directors on October 13, 2018. Prior to such date, he had served as Executive Chairman of the Board of Directors since October 13, 2016, as Chairman of the Board of Directors from January 25, 2007 to October 13, 2016, and as the Company’s Chief Executive Officer from March 1, 2007 to October 13, 2016. Dr. Rose has served as a director of SIGA since April 19, 2001 and served as Interim Chief Executive Officer of SIGA during April-June 2001. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012, which he now serves as professor. From 1994 through 2007, Dr. Rose served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. Dr. Rose is a graduate of both Columbia College and Columbia University College of Physicians & Surgeons. In addition to his roles at SIGA, Dr. Rose held a position as Executive Vice President – Life Sciences at MacAndrews & Forbes Incorporated, a related party to SIGA, until December 2016. In April 2013, he became a director for Mesoblast Inc. where he serves as chair of the scientific and technology committee. In 2015, Dr. Rose became a director of Abiomed, Inc. Dr. Rose’s experience and training as a practicing physician and a nationally recognized cardiothoracic surgeon enables him to bring valuable insight to the Board of Directors, including his understanding of the scientific aspects of our business and the ability to assist in prioritizing opportunities for drug development. In addition, Dr. Rose managed a large research portfolio and an extensive research and education budget at the Columbia Presbyterian Center, giving him a critical perspective on drug discovery and development and the issues facing pharmaceutical and biotechnology companies.
As the Chairman of the Board of SIGA Technologies Inc, the total compensation of Eric Rose at SIGA Technologies Inc is $319,500. There are 8 executives at SIGA Technologies Inc getting paid more, with Daniel Luckshire having the highest compensation of $1,684,000.
Eric Rose is 69, he's been the Chairman of the Board of SIGA Technologies Inc since 2018. There are 2 older and 9 younger executives at SIGA Technologies Inc. The oldest executive at SIGA Technologies Inc is Thomas Constance, 83, who is the Independent Director.
Eric's mailing address filed with the SEC is C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS, MA, 01923.
Over the last 21 years, insiders at SIGA Technologies Inc have traded over $65,185,125 worth of SIGA Technologies Inc stock and bought 6,065,626 units worth $33,817,674 . The most active insiders traders include Holdings Incperelman Ronald..., Pharma Inc Transtech, and Adnan M M Mjalli. On average, SIGA Technologies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $1,122,865. The most recent stock trade was executed by Dennis E Hruby on 1 July 2024, trading 32,258 units of SIGA stock currently worth $242,258.
at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.
SIGA Technologies Inc executives and other stock owners filed with the SEC include: